Sponsor

Luye Pharma Group Ltd.

Clinical research sponsor

Published trials47
Recruiting shown3
Roles2
SourceClinicalTrials.gov

Clinical trials

47 shown
A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020NCT07230652 · lead sponsor · 2025-08-20
RECRUITING
Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLCNCT06496048 · lead sponsor · 2024-09-14
RECRUITING
Study of LY01610 in Patients With Recurrent Small Cell Lung CancerNCT06128837 · lead sponsor · 2024-03-03
RECRUITING
A Phase 2 Study to Evaluate the Efficacy and Safety of LY03020 in Acutely Psychotic Participants With SchizophreniaNCT07396870 · lead sponsor · 2026-03-31
NOT_YET_RECRUITING
To Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Food Effects of LY03021 in Healthy Chinese SubjectsNCT07371065 · lead sponsor · 2025-10-28
ENROLLING_BY_INVITATION
A Food Effect Study of LY03020 in Healthy SubjectsNCT07292233 · lead sponsor · 2025-07-30
ACTIVE_NOT_RECRUITING
A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017NCT06980207 · lead sponsor · 2025-05-01
NOT_YET_RECRUITING
Effect of Food and Age on the Pharmacokinetics of LY03017NCT06793995 · lead sponsor · 2025-02-01
NOT_YET_RECRUITING
A Study Assessing the Safety and Tolerability of LY03020 in Chinese Healthy SubjectsNCT06556966 · lead sponsor · 2024-08-19
COMPLETED
To Evaluate the Long-term Efficacy and Safety of Toludevenlafaxine Hydrochloride Sustained-release TabletsNCT06426485 · lead sponsor · 2024-05-30
NOT_YET_RECRUITING
A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017NCT06388551 · lead sponsor · 2024-05-10
UNKNOWN
Pharmacokinetics Pharmacodynamics and Safety of LY01022 in Patients With Prostate Cancer Compared With Zoladex® 10.8mgNCT05856630 · lead sponsor · 2023-05-01
UNKNOWN
Comparing the Pharmacokinetic Profile of LY01612 and CAELYX® in Chinese Subjects With Advanced Breast CancerNCT06098599 · lead sponsor · 2022-05-17
COMPLETED
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective DisorderNCT05321602 · lead sponsor · 2021-09-08
COMPLETED
Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®NCT05140512 · lead sponsor · 2021-02-04
COMPLETED
to Evaluate the Safety, Tolerability and Pharmacokinetics of Four Formulations of LY03009 in Healthy VolunteersNCT04593511 · lead sponsor · 2021-02-02
UNKNOWN
Relative Bioavailability of LY03010 Compared to Listed DrugNCT04922593 · lead sponsor · 2021-01-13
COMPLETED
Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®NCT05110170 · lead sponsor · 2020-10-15
COMPLETED
Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung CancerNCT04381910 · lead sponsor · 2020-09-28
COMPLETED
A Study to Evaluate the Pharmacokinetics and Safety of LY03003 in Patients With Advanced-stage PDNCT04630860 · lead sponsor · 2020-07-07
COMPLETED
A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy VolunteersNCT04384666 · lead sponsor · 2020-06-02
COMPLETED
A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PDNCT04571164 · lead sponsor · 2020-05-11
COMPLETED
Evaluate the PK of LY03010 Process 1 and Process 2 Drug Product vs INVEGA SUSTENNA After Intramuscular Injection in Schizophrenia PatientsNCT04572685 · lead sponsor · 2020-01-22
COMPLETED
Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®NCT04563936 · lead sponsor · 2020-01-06
COMPLETED
A Relative Bioavailability Food Effect Study of LY03005NCT03822065 · lead sponsor · 2019-01-16
COMPLETED
A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia PatientsNCT03751488 · lead sponsor · 2018-12-12
COMPLETED
A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)NCT04853407 · lead sponsor · 2018-12-05
COMPLETED
A Study to Assess Pharmacokinetic Profiles of LY03003 and NeuproNCT03733561 · lead sponsor · 2018-11-09
COMPLETED
A Clinical Trial to Evaluate the Pharmacodynamics/Pharmacokinetics and Safety of LY03003 in Early PD PatientsNCT04629404 · lead sponsor · 2018-11-05
COMPLETED
A Study of LY03005 vs PristiqNCT03733574 · lead sponsor · 2018-06-19
COMPLETED
Pharmacokinetic Study of LY03003 in Patients With Parkinson's DiseaseNCT03589066 · lead sponsor · 2018-05-15
COMPLETED
A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate CancerNCT03450109 · lead sponsor · 2017-12-22
COMPLETED
A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung CancerNCT03533127 · lead sponsor · 2017-11-27
UNKNOWN
Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®NCT03357796 · lead sponsor · 2017-11-27
COMPLETED
A Multiple Ascending Dose Study With LY03003 in Patients With Early-stage Parkinson's DiseaseNCT04045678 · lead sponsor · 2017-10-10
COMPLETED
Pilot BA Study of New LY03005 vs PristiqNCT02988024 · lead sponsor · 2016-12-07
COMPLETED
Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's DiseaseNCT02728947 · lead sponsor · 2016-05-01
COMPLETED
Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LY03005 Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)NCT03785652 · lead sponsor · 2015-10-09
COMPLETED
Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005NCT02271412 · lead sponsor · 2014-10-01
COMPLETED
Bioavailability of LY03004 and Risperdal® Consta®NCT02091388 · lead sponsor · 2014-09-01
COMPLETED
An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective DisorderNCT02186769 · lead sponsor · 2014-07-01
COMPLETED
Safety, Tolerability and Pharmacokinetics Study of LY03005NCT02055300 · lead sponsor · 2014-02-01
COMPLETED
A Study of LY03003 in Patients With Early-stage Parkinson's DiseaseNCT04044547 · lead sponsor · 2013-11-22
COMPLETED
Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's DiseaseNCT02055274 · lead sponsor · 2013-10-01
COMPLETED
A Study to Evaluate the Human Tolerance and Pharmacokinetics of LY03003NCT04627155 · lead sponsor · 2013-03-15
COMPLETED
Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective DisorderNCT02055287 · lead sponsor · 2013-03-01
COMPLETED
Clinical Trial to Investigate Patch Adhesion of Rotigotine Containing Patches in Patients With Parkinson's DiseaseNCT06247410 · collaborator · 2021-08-23
COMPLETED

Sponsor roles

lead sponsor46
collaborator1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.